PH
PHH2.F Paul Hartmann AG
- Market cap
- EUR 675M
- P/E
- 6.8x
- P/B
- 0.55x
- ROE
- 5.2%
- Dividend yield
- 4.21%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is PHH2.F undervalued?
Graham numberPHH2.F trades 59.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Paul Hartmann AG fundamental analysis
No fundamental analysis for Paul Hartmann AG yet.
Paul Hartmann AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Paul Hartmann AG
Paul Hartmann AG manufactures and sells medical and care products in Germany, the rest of Europe, the Middle East, Africa, Asia and Pacific region, and the Americas. The company operates through three segments: Wound Care, Incontinence Management, and Infection Management. It offers absorbent underwear, incontinence pads and pants, and fixation pants; medical skincare products; wound management products, such as hydro active wound and silicone SAP dressings, post-op dressing…
Full company profilePaul Hartmann AG financial statements
Paul Hartmann AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.99B | 2.06B | 2.12B | 2.19B | 2.43B | 2.30B | 2.31B | 2.35B | 2.41B | 2.45B |
| Gross Profit | 1.14B | 1.18B | 1.22B | 1.24B | 1.38B | 1.31B | 1.31B | 1.32B | 1.44B | 1.48B |
| Operating Income | 101M | 115M | 102M | 71.0M | 136M | 113M | 30.9M | 33.9M | 114M | 97.5M |
| EBITDA | - | 208M | 196M | 212M | 309M | 236M | 167M | 168M | 249M | 235M |
| Net Income | 84.9M | 88.1M | 79.0M | 58.3M | 106M | 94.7M | 36.1M | 28.4M | 108M | 61.2M |
| EPS | - | 25 | 22 | 16 | 30 | 27 | 10 | 8.00 | 31 | 17 |
| Balance Sheet | ||||||||||
| Total Assets | 1.33B | 1.43B | 1.50B | 1.61B | 1.73B | 1.83B | 2.01B | 1.99B | 2.10B | 2.16B |
| Total Liabilities | 513M | 577M | 576M | 677M | 757M | 732M | 878M | 871M | 902M | 939M |
| Shareholders' Equity | 781M | 819M | 884M | 888M | 928M | 1.04B | 1.08B | 1.06B | 1.15B | 1.17B |
| Cash & Short-term Investments | 110M | 73.7M | 107M | 115M | 254M | 151M | 108M | 145M | 161M | 157M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 151M | 201M | 147M | 161M | 305M | 131M | -1.04M | 231M | 199M | 155M |
| Capital Expenditure | 68.0M | 65.7M | 84.7M | 85.7M | 112M | 129M | 118M | 113M | 139M | 126M |
| Free Cash Flow | - | 135M | 62.8M | 75.5M | 193M | 1.34M | -119M | 118M | 60.1M | 28.4M |
| Ratios | ||||||||||
| ROE | 10.9% | 10.8% | 8.9% | 6.6% | 11.5% | 9.1% | 3.4% | 2.7% | 9.4% | 5.2% |
| ROA | 6.4% | 6.2% | 5.3% | 3.6% | 6.2% | 5.2% | 1.8% | 1.4% | 5.2% | 2.8% |
| Net Profit Margin | 4.3% | 4.3% | 3.7% | 2.7% | 4.4% | 4.1% | 1.6% | 1.2% | 4.5% | 2.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Paul Hartmann AG dividends
- Dividend yield
- 4.21%
- Forward dividend
- 8.00 EUR
- Payout ratio
- 46.4%
- Ex-dividend date
- Apr 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 28.4M | 8.00 | 46.4% |
| 2024 | EUR 28.4M | 8.00 | 26.2% |
| 2023 | EUR 28.4M | 8.00 | 100.0% |
| 2022 | EUR 28.4M | 8.00 | 78.6% |
| 2021 | EUR 28.4M | 8.00 | 30.0% |
| 2020 | EUR 24.9M | 7.00 | 23.3% |
| 2019 | EUR 24.9M | 7.00 | 42.7% |
| 2018 | EUR 24.9M | 7.00 | 31.5% |
| 2017 | EUR 24.9M | 7.00 | 28.2% |
| 2016 | EUR 23.8M | - | 28.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Sep 25, 2000.
Who owns Paul Hartmann AG
- Insiders 0.00%
- Institutions 0.14%
- Public & others 99.87%
- Shares outstanding 3.55M
- Free float 3.55M
Paul Hartmann AG company profile
- Company name
- Paul Hartmann AG
- Ticker
- PHH2.F
- ISIN
- DE0007474041
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 9,881
- Fiscal year end
- December
- Address
- Paul-Hartmann-Strasse 12, Heidenheim, Germany, 89522
- Phone
- 49 7321 360
- Website
- hartmann.info
About Paul Hartmann AG
Paul Hartmann AG manufactures and sells medical and care products in Germany, the rest of Europe, the Middle East, Africa, Asia and Pacific region, and the Americas. The company operates through three segments: Wound Care, Incontinence Management, and Infection Management. It offers absorbent underwear, incontinence pads and pants, and fixation pants; medical skincare products; wound management products, such as hydro active wound and silicone SAP dressings, post-op dressings, nature care, adhesive fixation, non-adhesive fixation, gauze, sponges/tamponades, contact layers, absorption pads, cotton, and negative pressure wound therapy; compression, universal, zinc paste, and padding bandages; and hands, skin, surface, instruments, and equipment disinfection and hygiene products. In addition, the company sells operating theater products, including surgical drapes, operating theater clothing, surgical gloves, surgical absorbents and instruments; various Mediset products; patient care products, such as hygiene and maternity products, examination gloves, and nursing care products; diagnostics, such as blood pressure monitors, scale, and thermometers; first aid products; and cotton wool and cosmetic products. It sells its products under the CombiSet, DermaPlast, MoliCare, Sterillium, Veroval, and Zetuvit brands. Paul Hartmann AG was founded in 1818 and is headquartered in Heidenheim, Germany.
Paul Hartmann AG management
6- Ms. Britta FuenfstueckChairwoman of Management Board & CEO · born 1979
- Mr. Oliver NeubrandCFO & Member of Management Board · born 1970
- Mr. Francois GeorgelinMember of the Management Board
- Mr. Stefan GroteMember of the Management Board · born 1969
- Oliver EichelkrautInvestor Relations Officer
- Christian SievertSenior Vice President of Business Unit Risk Prevention